Late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases - Dermata Therapeutics ( NASDAQ: DRMA ) announced the sale of 1.91M shares and warrants to purchase shares at $1.83 per share.
Gross proceeds from the offering are expected to be approximately $3.5M. The closing of the offering is expected to occur on or about September 17, 2024.
The company expects to use net proceeds for general corporate purposes. The stock price dipped 3% on Monday during after-hours of trade. More on Dermata Therapeutics Seeking Alpha’s Quant Rating on Dermata Therapeutics Historical earnings data for Dermata Therapeutics Financial information for Dermata Therapeutics.
